cidofovir 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
antivirals phosphonic acid derivatives	639	113852-37-2

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: cidofovir cidofovir monophosphate cidovir vistide sidofovir cidofovir dihydrate anhydrous cidofovir cidofovir hydrate	An acyclic nucleoside phosphonate that acts as a competitive inhibitor of viral DNA polymerases. It is used in the treatment of RETINITIS caused by CYTOMEGALOVIRUS INFECTIONS and may also be useful for treating HERPESVIRUS INFECTIONS. Molecular weight: 279.19 Formula: C8H14N3O6P CLOGP: -1.99 LIPINSKI: 0 HAC: 9 HDO: 4 TPSA: 145.68 ALOGS: -1.38 ROTB: 6 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

cidofovir
cidofovir monophosphate
cidovir
vistide
sidofovir
cidofovir dihydrate
anhydrous cidofovir
cidofovir hydrate

An acyclic nucleoside phosphonate that acts as a competitive inhibitor of viral DNA polymerases. It is used in the treatment of RETINITIS caused by CYTOMEGALOVIRUS INFECTIONS and may also be useful for treating HERPESVIRUS INFECTIONS.

Molecular weight: 279.19
Formula: C8H14N3O6P
CLOGP: -1.99
LIPINSKI: 0
HAC: 9
HDO: 4
TPSA: 145.68
ALOGS: -1.38
ROTB: 6

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
25	mg	P

ADMET properties:

Show entries

Search:

Property	Value	Reference
EoM (Fraction excreted unchanged in urine)	90 %	Benet LZ, Broccatelli F, Oprea TI
BA (Bioavailability)	5 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
BDDCS (Biopharmaceutical Drug Disposition Classification System)	3	Benet LZ, Broccatelli F, Oprea TI
t_half (Half-life)	2.60 hours	Lombardo F, Berellini G, Obach RS
CL (Clearance)	2.50 mL/min/kg	Lombardo F, Berellini G, Obach RS
S (Water solubility)	170 mg/mL	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	17.91 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
fu (Fraction unbound in plasma)	1 %	Lombardo F, Berellini G, Obach RS
Vd (Volume of distribution)	0.49 L/kg	Lombardo F, Berellini G, Obach RS

Showing 1 to 9 of 9 entries

Previous1Next

Approvals:

Date	Agency	Company	Orphan
June 26, 1996	FDA	GILEAD SCIENCES INC

FDA Adverse Event Reporting System (Female)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Drug resistance	153.28	62.82	43	1231	22890	63464858
Adenovirus infection	139.49	62.82	28	1246	3543	63484205
BK virus infection	77.60	62.82	17	1257	3262	63484486
Cystitis haemorrhagic	73.73	62.82	17	1257	4106	63483642
Pathogen resistance	66.30	62.82	17	1257	6381	63481367
Nephropathy toxic	64.22	62.82	18	1256	9461	63478287
Cytomegalovirus infection reactivation	63.76	62.82	15	1259	3948	63483800

Showing 1 to 7 of 7 entries

Previous1Next

FDA Adverse Event Reporting System (Male)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Drug resistance	112.99	45.93	41	1303	25886	34929701
Cystitis haemorrhagic	93.96	45.93	25	1319	5654	34949933
Adenovirus infection	91.06	45.93	24	1320	5233	34950354
Off label use	70.81	45.93	83	1261	419441	34536146
Drug ineffective for unapproved indication	58.91	45.93	25	1319	23690	34931897
Cytomegalovirus infection	50.19	45.93	23	1321	26112	34929475
Pathogen resistance	48.79	45.93	17	1327	9465	34946122
Progressive multifocal leukoencephalopathy	48.30	45.93	17	1327	9747	34945840
Renal impairment	46.01	45.93	34	1310	94479	34861108

Showing 1 to 9 of 9 entries

Previous1Next

FDA Adverse Event Reporting System (Geriatric)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Drug resistance	256.24	49.78	82	2504	42131	79699671
Adenovirus infection	200.69	49.78	48	2538	8399	79733403
Cystitis haemorrhagic	151.76	49.78	39	2547	9133	79732669
Pathogen resistance	112.61	49.78	34	2552	14308	79727494
Epstein-Barr virus infection reactivation	101.69	49.78	21	2565	1871	79739931
Off label use	100.76	49.78	134	2452	907081	78834721
Nephropathy toxic	96.85	49.78	33	2553	20386	79721416
Cytomegalovirus infection	96.26	49.78	40	2546	42604	79699198
Immune reconstitution inflammatory syndrome	84.20	49.78	27	2559	13814	79727988
BK virus infection	82.75	49.78	24	2562	8780	79733022

Showing 1 to 10 of 16 entries

Previous1 2Next

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Show entries

Search:

Source	Code	Description
ATC	J05AB12	ANTIINFECTIVES FOR SYSTEMIC USE ANTIVIRALS FOR SYSTEMIC USE DIRECT ACTING ANTIVIRALS Nucleosides and nucleotides excl. reverse transcriptase inhibitors
CHEBI has role	CHEBI:35610	antineoplastic agents
CHEBI has role	CHEBI:36044	antiviral drugs
CHEBI has role	CHEBI:47868	photosensitising agent
CHEBI has role	CHEBI:64946	anti-AIDS agent
MeSH PA	D000890	Anti-Infective Agents
MeSH PA	D000998	Antiviral Agents
MeSH PA	D004791	Enzyme Inhibitors

Showing 1 to 8 of 8 entries

Previous1Next

Drug Use | Suggest Off label Use Form| |View source of the data|

Show entries

Search:

Disease	Relation	SNOMED_ID	DOID
CMV Retinitis in AIDS Patients	indication
Acyclovir-Resistant Mucocutaneous HSV in Immunocompromised Patients	indication
Prevention of Cytomegalovirus Disease	off-label use
Acidosis	contraindication	51387008
Kidney disease	contraindication	90708001	DOID:557
Severe Chronic Neutropenia	contraindication

Showing 1 to 6 of 6 entries

Previous1Next

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	4.81	acidic
pKa2	12.99	acidic
pKa3	4.1	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Show entries

Search:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
DNA polymerase catalytic subunit	Enzyme		DPOL_HHV11	INHIBITOR				WOMBAT-PK	CHEMBL

Showing 1 to 1 of 1 entries

Previous1Next

External reference:

Show entries

Search:

ID	Source
L8P	PDB_CHEM_ID
006053	NDDF
108688007	SNOMEDCT_US
149394-66-1	SECONDARY_CAS_RN
194597	MMSL
386894007	SNOMEDCT_US
4020976	VUID
4020976	VANDF
4446	MMSL
6016	MMSL

Showing 1 to 10 of 21 entries

Previous1 2 3Next

Pharmaceutical products:

Show entries

Search:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
CIDOFOVIR	HUMAN PRESCRIPTION DRUG LABEL	1	67457-210	INJECTION, SOLUTION	75 mg	INTRAVENOUS	ANDA	26 sections
CIDOFOVIR DIHYDRATE	HUMAN PRESCRIPTION DRUG LABEL	1	23155-216	INJECTION, SOLUTION	375 mg	INTRAVENOUS	ANDA	21 sections
Vistide	HUMAN PRESCRIPTION DRUG LABEL	1	61958-0101	INJECTION	75 mg	INTRAVENOUS	NDA	24 sections

Showing 1 to 3 of 3 entries

Previous1Next